ADC Therapeutics SA
Dosage regimes for the administration of an anti-CD19 ADC

Last updated:

Abstract:

The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCS).

Status:
Grant
Type:

Utility

Filling date:

14 Jun 2018

Issue date:

3 May 2022